<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Blood-based tests for the differential diagnosis of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) are under intensive investigation and have shown promising results with regard to Abeta40 and Abeta42 <z:chebi fb="7" ids="16670">peptide</z:chebi> species in incipient AD </plain></SENT>
<SENT sid="1" pm="."><plain>Moreover, plasma Abeta40 was suggested as an independent cerebrovascular risk factor candidate </plain></SENT>
<SENT sid="2" pm="."><plain>These considerations prompted us to analyse a total of 72 plasma samples in vascular <z:hpo ids='HP_0000726'>dementias</z:hpo> (VAD, n = 15), AD with cerebrovascular disease (AD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, n = 7), AD (n = 15), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> and <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> <z:hpo ids='HP_0000726'>dementia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>/PDD, n = 20) and 15 patients with <z:hpo ids='HP_0000716'>depression</z:hpo> that served as controls (DC) for distinct plasma amyloid-beta (Abeta) <z:chebi fb="7" ids="16670">peptide</z:chebi> patterns </plain></SENT>
<SENT sid="3" pm="."><plain>For the analysis of plasma we used immunoprecipitation followed by the quantitative Abeta-<z:chebi fb="26" ids="8984">SDS</z:chebi>-PAGE/immunoblot </plain></SENT>
<SENT sid="4" pm="."><plain>For comparison, CSF tau and Abeta1-42 analyses were performed </plain></SENT>
<SENT sid="5" pm="."><plain>The major outcome was an increase in Abeta1-40 in plasma of VAD paralleled by a decrease in the ratio of Abeta1-38/Abeta1-40 </plain></SENT>
<SENT sid="6" pm="."><plain>The ratio Abeta1-38/Abeta1-40 in plasma enabled contrasts of beyond 85% and 80% for discriminating VAD from DC and <z:hpo ids='HP_0000001'>all</z:hpo> other patients, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In CSF, we confirmed the typical CSF biomarker constellation of increased tau and diminished Abeta1-42 levels for AD </plain></SENT>
<SENT sid="8" pm="."><plain>The diagnostic accuracy of plasma Abeta1-38/Abeta1-40 for VAD resembled the accuracy of CSF biomarkers for AD </plain></SENT>
<SENT sid="9" pm="."><plain>From the presented results, we consider the ratio of plasma Abeta1-38/Abeta1-40 peptides to be a blood-based biomarker candidate for VAD </plain></SENT>
</text></document>